S. 2683 · 118th Congress
Accelerating Movement of Essential Rx Items to Create Access to National Drug Resources for US Government…
Full title
Accelerating Movement of Essential Rx Items to Create Access to National Drug Resources for US Government Services Act
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 118th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
R
ScottSponsor
Accelerating Movement of Essential Rx Items to Create Access to National Drug Resources for US Government Services Act or the AMERICAN DRUGS Act
What it does: CRS summary · Introduced in Senate · Jul 27, 2023
Accelerating Movement of Essential Rx Items to Create Access to National Drug Resources for US Government Services Act or the AMERICAN DRUGS Act
This bill generally limits coverage of generic drugs under federal health care programs to those that are manufactured domestically.
Specifically, the bill prohibits coverage of generic drugs that are manufactured in foreign countries under Medicare, Medicaid, the Children's Health Insurance Program (CHIP), TRICARE, and benefits provided by the Veterans' Administration. Coverage is permitted for foreign-made generic drugs if there are fewer than two other generic versions that are manufactured domestically or if the generic versions that are manufactured domestically are in shortage or soon to be discontinued. The Food and Drug Administration (FDA) must notify appropriate agencies about brand-name drugs that have at least two generic versions that are manufactured domestically and those that do not.
The bill also allows the FDA to expedite the development and review of applications for generic versions of brand-name drugs that do not have at least two generic versions that are manufactured domestically.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: AMERICAN DRUGS Act
Latest action (Jul 27, 2023): Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Policy area: Health · Origin: Senate · Introduced: Jul 27, 2023
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.